Omalizumab

Brand names: Omlyclo · Active ingredient: Omalizumab

In short: OMLYCLO is indicated for adults and pediatric patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Limitations of Use:

Forms & strengthsInjection: 75 mg/0.5 mL is a clear to opalescent and colorless to pale brownish- yellow solution in a single-dose prefilled syringe with yellow plunger rod and safety guard. …
LabelCELLTRION USA, Inc.
Label updatedOct 09, 2026

What is Omalizumab used for?

OMLYCLO is indicated for adults and pediatric patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.

Limitations of Use:

OMLYCLO is not indicated for the relief of acute bronchospasm or status asthmaticus.

OMLYCLO is indicated for add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

OMLYCLO is indicated for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.

OMLYCLO is to be used in conjunction with food allergen avoidance.

Limitations of Use:

OMLYCLO is not indicated for the emergency treatment of allergic reactions, including anaphylaxis.

OMLYCLO is indicated for the treatment of adults and adolescents 12 years of age and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.

Limitations of Use:

OMLYCLO is not indicated for treatment of other forms of urticaria.

âš  Boxed warning (FDA's strongest warning)

Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of omalizumab products. Anaphylaxis has occurred as early as after the first dose of omalizumab products, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, initiate OMLYCLO therapy in a healthcare setting and closely observe patients for an appropriate period of time after OMLYCLO administration. Health care providers administering OMLYCLO should be prepared to manage anaphylaxis which can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur. Selection of patients for self-administration of OMLYCLO should be based on criteria to mitigate risk from anaphylaxis [see Dosage and Administration (2.6), Warnings and Precautions (5.1) and Adverse Reactions (6.1, 6.2)].

Omalizumab dosage

Asthma, and Chronic Rhinosinusitis with Nasal Polyps, and IgE-Mediated Food Allergy

Determine dosage of OMLYCLO by serum total IgE level (IU/mL) measured before the start of treatment, and by body weight (kg).

For patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and IgE-mediated food allergy, dosage determination should be based on the primary diagnosis for which OMLYCLO is being prescribed.

Adjust doses for significant changes in body weight during treatment.

Refer to Tables 1 and 2 for the recommended dosage for treatment of asthma, Table 3 for treatment of CRSwNP, and Table 4 for treatment of IgE-mediated food allergy.

Total IgE levels are elevated during treatment and remain elevated for up to one year after the discontinuation of treatment. Therefore, re-testing of IgE levels during OMLYCLO treatment cannot be used as a guide for dose determination.

Interruptions lasting less than one year: Dose based on serum IgE levels obtained at the initial dose determination.

Interruptions lasting one year or more: Re-test total serum IgE levels for dose determination (Table 1 or 2 for treatment of asthma, based on the patient's age, Table 3 for treatment of CRSwNP, and Table 4 for treatment of IgE-mediated food allergy).

Chronic Spontaneous Urticaria

Dosage of OMLYCLO in patients with chronic spontaneous urticaria (CSU) is not dependent on serum IgE (free or total) level or body weight .

The recommended dosage for asthma is OMLYCLO 75 mg to 375 mg by subcutaneous injection every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and by body weight (kg) .

Adult and adolescent patients 12 years of age and older: Initiate dosing according to Table 1.

Pediatric patients 6 to <12 years of age: Initiate dosing according to Table 2.

Duration of Therapy

Periodically reassess the need for continued therapy based upon the patient's disease severity and level of asthma control.

The recommended dosage for chronic rhinosinusitis with nasal polyps (CRSwNP) is OMLYCLO 75 mg to 600 mg by subcutaneous injection every 2 or 4 weeks based on serum total IgE level (IU/mL) measure before the start of treatment and by body weight (kg) . Refer to Table 3 for recommended dosage based on serum total IgE level and body weight for patients with CRSwNP.

Duration of Therapy

Periodically reassess the need for continued therapy based upon the patient's disease severity and level of symptom control.

The recommended dosage for IgE-mediated food allergy is OMLYCLO 75 mg to 600 mg by subcutaneous injection every 2 or 4 weeks based on serum total IgE level (IU/mL), measured before the start of treatment, and by body weight . …

How to take Omalizumab — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Anaphylaxis

Inform patients of the risk of life-threatening anaphylaxis with OMLYCLO including the following points :

There have been reports of anaphylaxis occurring up to 4 days after administration of omalizumab products

Initiate OMLYCLO only in a healthcare setting by healthcare providers

Observe patients closely following administration

Inform patients of the signs and symptoms of anaphylaxis

Instruct patients to seek immediate medical care should such signs or symptoms occur

Potential Medication Error Related to Emergency Treatment of Anaphylaxis

Advise patients, parents, or caregivers that OMLYCLO should not be used for the emergency treatment of allergic reactions, including anaphylaxis .

Continuation of Other Medications

Instruct patients receiving OMLYCLO not to decrease the dose of, or stop taking any other asthma, CRSwNP, CSU or IgE-mediated food allergy medications or allergen immunotherapy unless otherwise instructed by their physician. …

Warnings & precautions

Do not take this medicine if: OMLYCLO is contraindicated in patients with severe hypersensitivity reaction to omalizumab products or any ingredient of OMLYCLO .

Anaphylaxis has been reported to occur after administration of omalizumab products in premarketing clinical trials and in postmarketing spontaneous reports . Signs and symptoms in these reported cases have included bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue. Some of these events have been life-threatening. In premarketing clinical trials in patients with asthma, anaphylaxis was reported in 3 of 3,507 (0.1%) patients. Anaphylaxis occurred with the first dose of omalizumab in two patients and with the fourth dose in one patient. The time to onset of anaphylaxis was 90 minutes after administration in two patients and 2 hours after administration in one patient.

A case-control study in asthma patients showed that, among omalizumab users, patients with a history of anaphylaxis to foods, medications, or other causes were at increased risk of anaphylaxis associated with omalizumab products, compared to those with no prior history of anaphylaxis .

In postmarketing spontaneous reports, the frequency of anaphylaxis attributed to omalizumab use was estimated to be at least 0.2% of patients based on an estimated exposure of 57,300 patients from June 2003 through December 2006. Anaphylaxis has occurred as early as after the first dose of omalizumab, but also has occurred beyond one year after beginning regularly scheduled treatment. Approximately 60% to 70% of anaphylaxis cases have been reported to occur within the first three doses of omalizumab, with additional cases occurring sporadically beyond the third dose.

Initiate OMLYCLO only in a healthcare setting equipped to manage anaphylaxis, which can be life-threatening. …

Omalizumab side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Anaphylaxis

Malignancies

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse Reactions from Clinical Studies in Adult and Adolescent Patients 12 Years of Age and Older with Asthma

The data described below reflect omalizumab exposure for 2,076 adult and adolescent patients ages 12 and older, including 1,687 patients exposed for six months and 555 exposed for one year or more, in either placebo-controlled or other controlled asthma studies. The mean age of patients receiving omalizumab was 42 years, with 134 patients 65 years of age or older; 60% were women, and 85% Caucasian. Patients received omalizumab 150 mg to 375 mg every 2 or 4 weeks or, for patients assigned to control groups, standard therapy with or without a placebo.

The adverse reactions most frequently resulting in clinical intervention (e.g., discontinuation of omalizumab, or the need for concomitant medication to treat an adverse reaction) were injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). These reactions were observed at similar rates in omalizumab-treated patients and control patients. …

Drug interactions

No formal drug interaction studies have been performed with omalizumab products.

In patients with asthma, CRSwNP, and IgE-mediated food allergy the concomitant use of omalizumab products and allergen immunotherapy has not been evaluated.

In patients with CSU, the use of omalizumab products in combination with immunosuppressive therapies has not been studied.

About this medicine

Omalizumab-igec is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that selectively binds to human immunoglobulin E (IgE). The antibody has a molecular weight of approximately 149 kiloDaltons. OMLYCLO is produced by a Chinese hamster ovary cell suspension culture.

OMLYCLO (omalizumab-igec) is administered as a subcutaneous (SC) injection and is available in prefilled syringes.

OMLYCLO Injection (Prefilled Syringe)

OMLYCLO (omalizumab-igec) injection is supplied as a sterile, preservative-free, clear to opalescent and colorless to pale brownish-yellow solution for subcutaneous injection.

OMLYCLO (omalizumab-igec) injection is available as a single-dose prefilled syringe.

Each 75 mg prefilled syringe delivers 75 mg omalizumab-igec in 0.5 mL and contains arginine hydrochloride (21.065 mg), histidine (0.685 mg), L-histidine hydrochloride monohydrate (1.17 mg), and polysorbate 20 (0.2 mg) in Water for Injection (WFI), USP. The pH of the product is 6.0. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID dbd8709f-1636-45d9-ba94-5a3bc5f22f84. Read the full official label on DailyMed.

Related medicines

Albuterol Montelukast Fluticasone Hydroxyzine Fluticasone and Salmeterol Budesonide and Formoterol Fluticasone and Umeclidinium and Vilanterol Azelastine